IMMUNITYBIO, INC. Other than Temporary Impairment Losses, Investments, Portion Recognized in Earnings, Net
IMMUNITYBIO, INC. (IBRX) reported Other than Temporary Impairment Losses, Investments, Portion Recognized in Earnings, Net of $0 for the 12-month period ending 2020-12-31, per its 10-K filed 2021-03-04.
Discontinued › Expense Statement › Operating Expenses
us-gaap:OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet · last filed 2021-03-04
- IMMUNITYBIO, INC. other than temporary impairment losses, investments, portion recognized in earnings, net for fiscal 2020 was $0.00.
- IMMUNITYBIO, INC. other than temporary impairment losses, investments, portion recognized in earnings, net for fiscal 2019 was $0.00.
- IMMUNITYBIO, INC. other than temporary impairment losses, investments, portion recognized in earnings, net for fiscal 2018 was $0.00.
- IMMUNITYBIO, INC. other than temporary impairment losses, investments, portion recognized in earnings, net for fiscal 2017 was $0.00.
| Period end | Other than Temporary Impairment Losses, Investments, Portion Recognized in Earnings, Net 12 month |
|---|---|
| 2020-12-31 | $0.00 10-K · filed 2021-03-04 |
| 2019-12-31 | $0.00 10-K · filed 2021-03-04 |
| 2018-12-31 | $0.00 10-K · filed 2021-03-04 |
| 2017-12-31 | $0.00 10-K · filed 2020-03-25 |
| 2016-12-31 | $0.00 10-K · filed 2019-03-13 |
| 2015-12-31 | $0.00 10-K · filed 2018-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 |